Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new public-private consortium (known as COMPACT) funded by the Innovative Medicines Initiative (IMI) of the EU recently launched a major new 30 million Euro project focussing on improving the delivery of biopharmaceutical drugs. The University of Oxford plays a leading
role in the consortium which also comprises experts from 14 academic institutions, two biotechnology companies and seven pharmaceutical companies. Professor Matthew Wood will lead all IMI work to develop improved methods for drug delivery to the brain. A major challenge in treating many currently incurable neurological diseases is to achieve effective drug delivery to the brain across the blood brain barrier (a natural barrier that protects the brain). This new IMI project aims to tackle this challenge within the next 5 years.

Similar stories

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Professor Dame Frances Ashcroft to receive Vanderbilt Prize in Biomedical Science

The Vanderbilt Prize in Biomedical Science recognises women scientists with a stellar record of research accomplishments who also have made significant contributions to mentoring other women in science.

Annie Park to advance our understanding of how the brain encodes reward with new Wellcome Trust Award

Congratulations are in order for Postdoctoral Fellow Dr Annie Park who has been awarded a prestigious Wellcome Early-Career Award.

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Unlocking the Secrets of cAMP Signalling in the Heart: A Pathway to Targeted Therapeutics

A new Zaccolo group study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. They have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.